IOVS Applied and Environmental Microbiology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hasebe, Y.
Right arrow Articles by Dorey, C. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hasebe, Y.
Right arrow Articles by Dorey, C. K.
(Investigative Ophthalmology and Visual Science. 2000;41:2774-2778.)
© 2000 by The Association for Research in Vision and Ophthalmology, Inc.

Pentoxifylline Inhibition of Vasculogenesis in the Neonatal Rat Retina

Yasuko Hasebe1, Lauren R. Thomson2 and C. Kathleen Dorey3

From the Schepens Eye Research Institute and Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts.


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
PURPOSE. The zeta isozyme of protein kinase C (PKC) is essential for activation of the transcription factor nuclear factor (NF){kappa}B and transcription of vascular endothelial growth factor (VEGF). This study examined the antiangiogenic potential of an existing drug, pentoxifylline (PTX), which inhibits PKC-dependent activation of NF{kappa}B and is reported to prevent hypoxia-induced expression of VEGF.

METHODS. Neovascularization was induced by maintaining neonatal rats for 10 full days in 80% oxygen, interrupted daily by 30 minutes in room air followed by a progressive return to 80% oxygen. On experimental day 11, they were placed in room air until they were killed on day 17. Daily intraperitoneal injections of PTX in saline (25 or 75 mg/kg per day), or saline alone, were administered from day 6 through day 16. Retinal neovascularization was scored, and avascular areas (AVAs) were measured in ADPase stained retinas.

RESULTS. PTX inhibited radial extension of retinal vessels, causing increases in AVA of 65% (P < 0.01) and 33% (P < 0.15) at the lower and upper doses, respectively. A significant increase in mean neovascular score was seen at the lower dose (P < 0.0001), but analysis of variance indicated that neovascularization was strongly and positively influenced by the AVA (P < 0.0001) and only weakly stimulated by PTX (P < 0.05).

CONCLUSIONS. Systemic PTX significantly inhibited VEGF-mediated retinal vasculogenesis, but was not effective in reducing neovascularization in the oxygen-exposed neonatal rat.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
In the developing rat retina, hypoxia-induced expression of vascular endothelial growth factor–vascular permeability factor (VEGF) in the avascular peripheral retina1 drives vasculogenesis (de novo formation of new vessels from angioblasts,2 which may proliferate before their assembly into tubes3 ). VEGF also induces neovascularization (growth of new vessels in aberrant patterns) through angiogenesis (growth from existing vessels),4 and incorporation of bone marrow–derived endothelial cell progenitors (vasculogenesis).5 Experimentally induced neovascularization has been spatially and temporally correlated with elevated expression of VEGF in the retina and/or vitreous.6 7 8

Hypoxia-induced transcription of VEGF is mimicked by exposure to cobalt, which induces formation of reactive oxygen species and activation of nuclear factor (NF){kappa}B.9 Activation of NF{kappa}B is critically dependent on the atypical zeta isozyme of protein kinase C (PKC{zeta}) in fibroblasts10 and endothelial cells.11 Recent evidence indicates that PKC{zeta} plays a decisive role in the transcription of VEGF,12 and VEGF-stimulated endothelial cell proliferation.13 Pentoxifylline (PTX), a methylxanthine derivative that inhibits the PKC-dependent activation of NF{kappa}B,14 15 also suppresses hypoxia-induced expression of VEGF.16 Nonspecific PKC inhibitors and inhibition of NF{kappa}B suppress neovascularization.17 18 The purpose of these experiments was to determine whether systemic PTX inhibits neovascularization in a rat model of retinopathy of prematurity. PTX was of particular interest because, it was reported to increase retinal and choroidal blood flow in patients with diabetes and age-related macular degeneration.19 20 21 Moreover, PTX had suppressed neovascularization in rabbit corneas injected with oxidized lipids22 and was reported to reduce neovascularization in 27 patients with retinal hemorrhages.23

Data from the current study demonstrate that PTX effectively inhibited vasculogenesis in the oxygen-exposed neonatal rat retina, causing significantly increased avascular areas (AVAs). Neovascular responses to the enlarged AVAs were mildly stimulated by PTX.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
Rat Model of Ischemic Retinopathy
Neovascularization is reproducibly observed in neonatal rats placed for 10 full days in elevated oxygen interrupted daily by an episode of relative hypoxia in room air and then transferred on day 11 to room air for 7 additional days.24 Oxygen exposure reduces VEGF production25 and impairs development of retinal vessels.24 When the 11-day-old rats are placed in a room air environment, the hypoxic consequences of the enlarged peripheral AVA stimulate expression of VEGF.7 Both the incidence and the intensity of the neovascular response are highly correlated with the area of peripheral avascular retina7 24 and with the duration of the hypoxic episodes.24 Almost 90% of the neovascularization was observed in the inferior quadrant, which has the largest AVA. The superior quadrant, with little AVA, has negligible neovascularization.24

Experimental Protocol
Animals were treated in accordance with a protocol approved by the institutional Animal Care and Use Committee and with the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research. For each experiment, neonates from six albino Sprague–Dawley rats with timed pregnancy (Charles River, Kingston, NY) were divided into three equal litters in oxygen (10–15 pups, depending on the number of pups born) and three smaller litters in room air. Mothers were rotated between room air and oxygen every 2 days. From days 6 through 16, room air– and oxygen-exposed animals were given intraperitoneal injections of either PTX (25 or 75 mg/kg; prepared fresh daily) or phosphate-buffered saline vehicle (0.137 M, pH 7.4; Boehringer–Mannheim, Indianapolis, IN). The oxygen-exposed animals received five treatments in oxygen (days 6 through 10) and six in room air (days 11 through 16) before they were killed on day 17. The doses of PTX used in these experiments were within the range for rats in the literature and varied by a factor of 3. The results of three independent experiments are presented. Eighty-one oxygen-exposed animals were treated with 25 mg PTX/kg (n = 19), 75 mg PTX/kg (n = 29), or saline (n = 33). All animals were treated, killed, processed, and analyzed in parallel. One retina from every animal was processed, and every retina was included in the analysis. Unless otherwise indicated, all chemicals were from Sigma (St. Louis, MO).

Retina Processing
Enucleated eyes were fixed 24 to 48 hours in 4% paraformaldehyde (Polysciences, Warrington, PA) in cacodylate buffer (0.1 M, pH7.2). After the retina was freed from vitreous and the eyecup, the retinal vessels were revealed by adenosine diphosphatase (ADPase) histochemistry, scored, and flatmounted as previously described.24

Neovascular Scores and Image Analysis
Neovascularization, recognized as structures that are abnormal in architecture and intensely stained with ADPase, included intravitreal knots of capillaries (glomerular buds), fan-shaped vascular fronds, and thickened vascular ridges that elevated the retinal surface and ran parallel to the ciliary body (perpendicular to the radial arteries and veins). The intensity of neovascularization in each retina was determined as the total of individual quadrant scores, using a minor modification of previously published criteria (Table 1) .7


View this table:
[in this window]
[in a new window]
  		Table 1. Criteria for Scoring Neovascular Intensity

 
Avascular Area
Digital images of the mounted ADPase-stained retinas were acquired using a CCD video camera (Hamamatsu CCD; Dage–MTI, Michigan City, IN). The peripheral avascular retina of every quadrant in one eye from each animal was traced (Fig. 1) and measured in square millimeters by computer (NIH Image software; National Institutes of Health, Bethesda, MD; installed on a Power Tower 250; Power Computing, Round Rock, TX). Significant interexperimental variation (P < 0.0001; analysis of variance [ANOVA]) made it necessary to compare areas of treated animals with controls from the same experiment. To determine the effect of treatment on AVA (and for this analysis only) each measurement of area was expressed as a percentage of the mean area in the vehicle-injected, oxygen-exposed control samples from the same experiment. This corrected measurement of area was designated as AVA (%) or AVA%.



View larger version (67K):
[in this window]
[in a new window]
  		Figure 1. Digital images of retinas from animals given daily intraperitoneal injections of PTX (left) or vehicle (right) from experimental days 6 through 16. There were no PTX-induced abnormalities in vessel architecture. The AVA in one quadrant of the vehicle retina is outlined; the inner retina is rolled back at *. Neovascular score (NV) and AVA in square millimeters are given for each retina. Magnification, x9.5.

 
Statistical Analysis
ANOVA and multiple regression routines in commercial software (Statview ver. 4.5; Abacus Concepts, Berkeley, CA) were used to assess the influence of PTX on AVA and on neovascularization. Comparisons between groups were performed with Fishers’ protected least-significant difference procedure for multiple comparisons. The relative contribution of AVA and PTX dose to the observed neovascular response was analyzed by multiple regression.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
Treatment with PTX had no effect on vascular pattern, but caused striking increases in the area of avascular retina (Fig. 1) . The mean AVA% increased 65% in animals given 25 mg PTX/kg (P < 0.01; ANOVA) and 33% in those treated with 75 mg PTX/kg (P < 0.15). There was no significant difference between the two treatments (P = 0.2; Fig. 2 ). When all PTX-treated animals (i.e., regardless of dose) were compared with all controls, there was still a significant PTX-induced increase in AVA% (P < 0.03; ANOVA).



View larger version (41K):
[in this window]
[in a new window]
  		Figure 2. (A) Area (in square millimeters) of avascular retina in animals given intraperitoneal injections of saline containing 0, 25, or 75 mg/kg PTX. Animals given 25 mg/kg had significantly larger AVAs than animals injected with saline. Those given the higher dose tended to have larger AVAs than the control animals but were not significantly different from those given 25 mg/kg (P = 0.2). Data are means ± SE, expressed as a percentage of the vehicle controls in each experiment (**P < 0.01; ANOVA). (B) Neovascular scores in animals given intraperitoneal injections of saline containing 0, 25, or 75 mg/kg PTX. Animals treated with 25 mg/kg had higher neovascular scores than controls or those given the higher dose. Data are means ± SE (**P < 0.01; ****P < 0.0001; ANOVA).

 
Neovascular scores were significantly increased in animals treated with 25 mg PTX/kg, the group that also had the largest AVAs (Fig. 2B) . As seen in Figure 3 , neovascular scores increased with increase in AVA in all treatment groups, and the regression lines overlapped. Although r2 > 0.5, and P < 0.0001 (Table 2) indicated that each of the regression lines in Figure 3 were reasonable estimates of the data, overlaps in the 95% confidence intervals for the slopes and intercepts indicated they were not significantly different from each other. Therefore, multiple regression analysis (Table 3) was used to assess the relationship between neovascular scores and AVA, drug dose, and/or the interaction of the two. The resultant R2 indicated that 65% of the observed variation in neovascular scores could be attributed to the combined positive influences of AVA (P < 0.0001) and drug dose (P < 0.05). Moreover, the influence of AVA was almost six times greater than the effect of PTX (standard coefficients 0.81 and 0.14, respectively). The interaction term was not significant (P > 0.6) and was omitted from the model.



View larger version (20K):
[in this window]
[in a new window]
  		Figure 3. Relationship between the AVA and neovascular score in 81 animals treated with 25 or 75 mg/kg PTX or saline. The three regression lines are not significantly different, in that they have overlapping coefficients for slope and intercept (Table 2) . Multiple regression analysis resulted in the model in Table 3 .

 

View this table:
[in this window]
[in a new window]
  		Table 2. Regression Analysis of the Relation between Neovascular Score and AVA in Animals Given Saline or PTX

 

View this table:
[in this window]
[in a new window]
  		Table 3. Multiple Regression Model

 

   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
The strong inhibition of vasculogenesis in the oxygen-exposed rat retina is consistent with reports that PTX inhibits hypoxia-induced expression of VEGF,16 and evidence that vasculogenesis fails if VEGF signaling is disrupted.26 27 28 Recent literature suggests that PTX inhibits hypoxia-induced transcription and production of VEGF12 16 and VEGF-induced proliferation of endothelial cells13 or angioblasts. Both activities would slow vasculogenesis and reduce survival of newly formed vessels.25 However, because VEGF was not measured in these retinas, the possibility that PTX acted through a different mechanism cannot be excluded.

Failure to Inhibit Neovascularization
The observed stimulation of neovascularization is inconsistent with previous reports that PTX inhibits neovascularization in a rabbit corneal model22 and in a small number of patients with vitreous hemorrhage,23 and with a recent report that pyrrolidine dithiocarbamate, another inhibitor of NF{kappa}B activation, suppresses retinal neovascularization in mice.29 Multivariate analysis indicated that the increases in neovascularization were primarily due to the hypoxic consequences of PTX inhibition of vasculogenesis (i.e., the PTX-induced increase in AVA). The PTX-induced increase was small and barely significant. Possible explanations for this observation include (among others) participation of angiogenic factors not sensitive to PTX, stimulation of neovascularization through inhibition of phosphodiesterase by PTX, and/or pharmacokinetic considerations.

Because VEGF expression is upregulated in the AVAs, and because PTX resulted in even larger AVAs, it is clear that the proangiogenic stimulus would be greater in the PTX-treated animals. The most parsimonious explanation for the observed absence of effect on neovascularization is that the PTX was sufficient to tip the balance of pro- and antiangiogenic factors regulating intraretinal vessel growth during periods of hyperoxia, but was not sufficiently antiangiogenic to suppress neovascular responses to higher levels of VEGF7 8 and/or other angiogenic factors produced by the enlarged AVAs in the PTX-treated animals. The ability of PTX to have a deciding influence on the balance of pro- and antiangiogenic factors may be exacerbated by reduced clearance of PTX during periods of hyperoxia. Blood flow in the retina and/or optic nerve head was reduced 25% to 30% in human subjects breathing 100% oxygen.30 31 If blood flow in neonatal mice were similarly reduced during periods of hyperoxia, it is feasible that intraretinal vessel growth would be exposed to higher average levels of PTX than those present during the final days in room air when the neovascular growth was most active.

The differential effects observed in this model may also derive from the opposing effects of PTX on two pathways stimulating VEGF expression in hypoxic tissues. Vasculogenesis is primarily dependent on the hypoxia-induced expression of VEGF.1 25 26 27 28 32 Recent evidence indicates that this pathway is PKC{zeta}-dependent12 13 and inhibited by PTX.15 16 Another pathway may also be important in neovascularization. Adenosine accumulating in hypoxic retina33 can activate A-2 receptors on endothelial cells, stimulating a rise in cyclic adenosine monophosphate (cAMP) and increased transcription of VEGF.34 35 Although PTX is an inefficient phosphodiesterase inhibitor, the doses used in these experiments may have achieved concentrations sufficient (~10-4 M)36 to elevate cAMP and thus increase VEGF in hypoxic endothelial cells. This explanation would be consistent with the stronger inhibition of vasculogenesis at the lower dose of PTX, and further suggests that adenosine may play a significant role in the neovascular response to large areas of ischemic retina.

Clinical Implications
Small clinical studies have suggested beneficial effects of PTX on retinal blood flow and appearance of microvascular abnormalities.19 20 21 37 The present data and prior evidence that PTX inhibited corneal neovascularization in rabbits22 and extraretinal neovascularization in patients23 suggest that PTX at appropriate doses may inhibit vasculogenesis and/or neovascularization. Both retinal vasculogenesis (data shown here) and corneal neovascularization were sensitive to PTX, and both involve the recruitment of endothelial precursors.1 5 Although far from perfect, PTX may have some application for neovascularization associated with inflammation, until newer more effective drugs are available. However, the use of PTX in proliferative retinopathies is limited by the possibility of exacerbating neovascular responses to retinal ischemia. In conclusion, systemic treatment with PTX inhibited vasculogenesis, but not neovascularization, in the rat model of retinopathy of prematurity.


   Footnotes
 
1 Present address: Department of Ophthalmology, Showa University School of Medicine, Hatanodai 1-5-8, Shinagawa, Tokyo 142, Japan. Back

2 Present address: School of Medicine, State University of New York, Brooklyn. Back

3 Present address: R&D Consulting, Arlington, Massachusetts. Back

Presented at the annual meeting of the Association for Research in Vision and Ophthalmology, Fort Lauderdale, Florida, May 1998.

Supported by a grant from the Retina Research Foundation, Houston, Texas.

Submitted for publication July 29, 1998; revised October 4, 1999 and March 29, 2000; accepted April 13, 2000.

Commercial relationships policy: N.

Corresponding author: C. Kathleen Dorey, R&D Consulting, 15 Draper Avenue, Arlington, MA 02474. kdorey{at}earthlink.net


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Stone, J, Itin, A, Alon, T, et al (1995) Development of retinal vasculature is mediated by hypoxia-induced vascular endothelial growth factor (VEGF) expression by neuroglia J Neurosci 15,4738-4747[Abstract]
  2. McLeod, DS, Lutty, GA, Wajer, SD, Flower, RW (1987) Visualization of a developing vasculature Microvasc Res 33,257-269[Medline][Order article via Infotrieve]
  3. Chan-Ling, T, Gock, B, Stone, J. (1995) The effect of oxygen on vasoformative cell division: evidence that "physiological hypoxia" is the stimulus for normal retinal vasculogenesis Invest Ophthalmol Vis Sci 36,1201-1214[Abstract/Free Full Text]
  4. Kenyon, BM, Voest, EE, Chen, CC, Flynn, E, Folkman, J, D’Amato, RJ (1996) A model of angiogenesis in the mouse cornea Invest Ophthalmol Vis Sci 37,1625-1632[Abstract/Free Full Text]
  5. Asahara, T, Takahasi, T, Masuda, H, et al (1999) VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells EMBO J 18,3964-3972[Medline][Order article via Infotrieve]
  6. Miller, JW, Adamis, AP, Shima, DT, et al (1994) Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model Am J Pathol 145,574-584[Abstract]
  7. Dorey, CK, Aouididi, S, Reynaud, X, Dvorak, HF, Brown, LF (1996) Correlation of vascular permeability factor/vascular endothelial growth factor with extraretinal neovascularization in the rat Arch Ophthalmol 114,1210-1217[Abstract/Free Full Text]
  8. Donahue, ML, Phelps, DL, Watkins, RH, LoMonaco, MB, Horowitz, S. (1996) Retinal vascular endothelial growth factor (VEGF) mRNA expression is altered in relation to neovascularization in oxygen induced retinopathy Curr Eye Res 15,175-184[Medline][Order article via Infotrieve]
  9. Goebeler, M, Roth, J, Brocker, EB, Sorg, C, Schulze–Osthoff, K. (1995) Activation of nuclear factor-kappa B and gene expression in human endothelial cells by the common haptens nickel and cobalt J Immunol 155,2459-2467[Abstract]
  10. Diaz–Meco, MT, Berra, E, Municio, MM, et al (1993) A dominant negative protein kinase C zeta subspecies blocks NF-kappa B activation Mol Cell Biol 13,4770-4775[Abstract/Free Full Text]
  11. Anrather, J, Csizmadia, V, Soares, MP, Winkler, H. (1999) Regulation of NF-kappaB RelA phosphorylation and transcriptional activity by p21(ras) and protein kinase Czeta in primary endothelial cells J Biol Chem 274,13594-13603[Abstract/Free Full Text]
  12. Pal, S, Claffey, K, Cohen, H, Mukhopadhyay, D. (1998) Activation of Sp1-mediated vascular permeability factor/vascular endothelial growth factor transcription requires specific interaction with protein kinase C zeta J Biol Chem 273,26277-26280[Abstract/Free Full Text]
  13. Wellner, M, Maasch, C, Kupprion, C, Lindschau, C, Luft, FC, Haller, H. (1999) The proliferative effect of vascular endothelial growth factor requires protein kinase C-alpha and protein kinase C-zeta Arterioscler Thromb Vasc Biol 19,178-185[Abstract/Free Full Text]
  14. Mhashilkar, AM, Biswas, DK, LaVecchio, J, Pardee, AB, Marasco, WA (1997) Inhibition of human immunodeficiency virus type 1 replication in vitro by a novel combination of anti-Tat single-chain antibodies and NF-kappa B antagonists J Virol 71,6486-6494[Abstract]
  15. Biswas, DK, Ahlers, CM, Dezube, BJ, Pardee, AB (1994) Pentoxifylline and other protein kinase C inhibitors down-regulate HIV-LTR NF-kappa B induced gene expression Mol Med 1,31-43[Medline][Order article via Infotrieve]
  16. Amirkhosravi, A, Meyer, T, Warnes, G, et al (1998) Pentoxifylline inhibits hypoxia-induced upregulation of tumor cell tissue factor and vascular endothelial growth factor Thromb Haemost 80,598-602[Medline][Order article via Infotrieve]
  17. Hu, DE, Fan, TP (1995) Protein kinase C inhibitor calphostin C prevents cytokine-induced angiogenesis in the rat Inflammation 19,39-54[Medline][Order article via Infotrieve]
  18. Stoltz, RA, Abraham, NG, Laniado–Schwartzman, M. (1996) The role of NF-kappaB in the angiogenic response of coronary microvessel endothelial cells Proc Natl Acad Sci USA 93,2832-2837[Abstract/Free Full Text]
  19. Sonkin, PL, Kelly, LW, Sinclair, SH, Hatchell, DL (1993) Pentoxifylline increases retinal capillary blood flow velocity in patients with diabetes Arch Ophthalmol 111,1647-1652[Abstract/Free Full Text]
  20. Sebag, J, Tang, M, Brown, S, Sadun, AA, Charles, MA (1994) Effects of pentoxifylline on choroidal blood flow in nonproliferative diabetic retinopathy Angiology 45,429-433
  21. Kruger, A, Martulla, B, Wolzt, M, et al (1998) Short-term oral pentoxifylline use increases choroidal blood flow in patients with age related macular degeneration Arch Ophthalmol 116,27-30[Abstract/Free Full Text]
  22. Ueda, T, Ueda, T, Fukuda, S, et al (1997) Lipid hydroperoxide induced TNF{alpha}, VEGF, and neovascularization in the rabbit cornea: effect of TNF{alpha} inhibition Angiogenesis 1,174-184
  23. Iwafune, Y, Yoshimoto, H. (1980) Clinical use of pentoxifylline in haemorrhagic disorders of the retina Pharmatherapeutica 2,429-438[Medline][Order article via Infotrieve]
  24. Reynaud, X, Dorey, CK (1994) Extraretinal neovascularization induced by hypoxic episodes in the neonatal rat Invest Ophthalmol Vis Sci 35,3169-3177[Abstract/Free Full Text]
  25. Alon, T, Hemo, I, Itin, A, Pe’er, J, Stone, J, Keshet, E. (1995) Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity Nat Med 1,1024-1028[Medline][Order article via Infotrieve]
  26. Shalaby, F, Rossant, J, Yamaguchi, T, et al (1995) Failure of blood island formation and vasculogenesis in Flk-1 deficient mice Nature 376,62-66[Medline][Order article via Infotrieve]
  27. Carmeliet, P, Ferreira, V, Breier, G, et al (1996) Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele Nature 380,435-439[Medline][Order article via Infotrieve]
  28. Ferrara, N, Carver–Moore, K, Chen, H, et al (1996) Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene Nature 380,439-442[Medline][Order article via Infotrieve]
  29. Yoshida, A, Yoshida, S, Ishibashi, T, Kuwano, M, Inomata, H. (1999) Suppression of retinal neovascularization by the NF-kappaB inhibitor pyrrolidine dithiocarbamate in mice Invest Ophthalmol Vis Sci 40,1624-1629[Abstract/Free Full Text]
  30. Langhans, M, Michelson, G, Groh, MJ (1997) Effect of breathing 100% oxygen on retinal and optic nerve head capillary blood flow in smokers and non-smokers Br J Ophthalmol 81,365-369[Abstract/Free Full Text]
  31. Harris, A, Anderson, DR, Pillunat, L, et al (1996) Laser Doppler flowmetry measurement of changes in human optic nerve head blood flow in response to blood gas perturbations J Glaucoma 5,258-265[Medline][Order article via Infotrieve]
  32. Aiello, LP, Northrup, JM, Keyt, BA, Takagi, H, Iwamoto, MA (1995) Hypoxic regulation of vascular endothelial growth factor in retinal cells Arch Ophthalmol 113,1538-1544[Abstract/Free Full Text]
  33. Ghiardi, GJ, Gidday, JM, Roth, S. (1999) The purine nucleoside adenosine in retinal ischemia-reperfusion injury Vision Res 39,2519-2535[Medline][Order article via Infotrieve]
  34. Takagi, H, King, GL, Robinson, GS, Ferrara, N, Aiello, LP (1996) Adenosine mediates hypoxic induction of vascular endothelial growth factor in retinal pericytes and endothelial cells Invest Ophthalmol Vis Sci 37,2165-2176[Abstract/Free Full Text]
  35. Cheng, T, Cao, W, Wen, R, Steinberg, RH, LaVail, MM (1998) Prostaglandin E2 induces vascular endothelial growth factor and basic fibroblast growth factor mRNA expression in cultured rat Muller cells Invest Ophthalmol Vis Sci 39,581-591[Abstract/Free Full Text]
  36. Meskini, N, Nemoz, G, Okyayuz–Baklouti, I, Lagarde, M, Prigent, AF (1994) Phosphodiesterase inhibitory profile of some related xanthine derivatives pharmacologically active on the peripheral microcirculation Biochem. Pharmacol. 47,781-788[Medline][Order article via Infotrieve]
  37. Ferrari, E, Fioravanti, M, Patti, AL, Viola, C, Solerte, SB (1987) Effects of long-term treatment (4 years) with pentoxifylline on haemorheological changes and vascular complications in diabetic patients Pharmatherapeutica 5,26-39[Medline][Order article via Infotrieve]



This article has been cited by other articles:


Home page
 IOVSHome page
A. J. Franklin, T. L. Jetton, C. L. Kuchemann, S. R. Russell, and E. C. Kohn
CAI Is a Potent Inhibitor of Neovascularization and Imparts Neuroprotection in a Mouse Model of Ischemic Retinopathy
Invest. Ophthalmol. Vis. Sci., October 1, 2004; 45(10): 3756 - 3766.
[Abstract] [Full Text] [PDF]

Home page
 Br. J. Ophthalmol.Home page
A C S. Ventura and M Bohnke
Pentoxifylline influences the autocrine function of organ cultured donor corneas and enhances endothelial cell survival
Br. J. Ophthalmol., September 1, 2001; 85(9): 1110 - 1114.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hasebe, Y.
Right arrow Articles by Dorey, C. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hasebe, Y.
Right arrow Articles by Dorey, C. K.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS